Cavaltinib®

Helping survive the cytokine storm.

We have seen how COVID-19 can be fatal under certain conditions. However, we mustn't lose sight of the fact that the common influenza can, itself, be fatal to those at risk of morbidity. In fact, respiratory disease is on the rise as our environment evolves and infectious diseases become more pervasive. How do these symptoms of human evolution factor into the state of human health in the near and distant future?

Asthma and COPD are common with over 50 million diagnosed in the USA and many more with subclinical levels of the diseases yet to be diagnosed. Annual health care costs in the USA alone for respiratory disease is said to be in excess of 21 billion dollars annually and with the recent impact by COVID-19, this number is sure to be tripled.



The complications that can lead to advanced morbidity and even mortality are often related more to the immune system’s heightened reactivity to infection or irritation. In the case of COVID-19, for instance, patient predisposition to exacerbated immune and inflammatory response leads to the ‘cytokine storm’ phenomenon we’ve heard talk about – an overloaded assault by immune system cells and biochemicals. This is, in fact, the mechanism by which most of the COVID-19 deaths are occurring.

The high risk factors for such COVID-19 patients can include but are not limited to obesity, advanced age, autoimmune disease, asthma, COPD and diabetes. Patients with one or more of these conditions can be seriously harmed and even expire by way of COVID-19. Even those that survive can have long-term, life changing health consequences. With our work we hope to change the course of this disease and the risk it poses to humanity. Through our work, we hope to make CavaltinibTM available as a reliable drug for the treatment of COVID-19, a serious malady that reaches beyond just respiratory disease, and other diseases related to respiratory distress.



CavaltinibTM has been shown to inhibit elevated cytokine status upstream of the cytokine storm; at the level where these cytokines are made, thus slowing down the assault to a more controlled immune response. In the immediate term, the COVID-19 model serves as a perfect opportunity to showcase Cavaltinib’s drug activity. This pharmacology allows the patient to survive the cytokine storm stage and make it through to the antibody stage (adaptive immunity). Those that survive the cytokine storm are theoretically able to develop antibodies and go on to recover and, in most cases, build immunity against re-infection.

While research is showing that this is not consistent from patient to patient, managing the storm is central to survival.

Published peer reviewed findings show that CavaltinibTM inhibits a group of key inflammatory cytokines including and especially IL-6. Many clinical trials are targeting just one cytokine as the mechanism for the therapeutic process in the COVID-19 disease model and that’s only a small part of the solution.

CavaltinibTM can help the patient survive this inflammatory storm by inhibiting several key cytokines at once, providing a window of opportunity for antibody generation by way of natural immunity. With our work we hope to establish a model for the treatment of this COVID-19 crisis, future viral threats that may pose similar risks, and other respiratory diseases that are taking our breath away.